PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response Non-Interventional Study

NCT07648602 | Recruiting

• 1 other identifier: CorEvitas-PSO-525
• Study Type: observational
• Target: 2,500
• Locations: 1 country
• Sites: 2

Brief Summary

This is a 24-week prospective, single-arm cohort, study of patients initiating advanced therapy for the treatment of moderate-to-severe plaque PSO. Eligible patients must be willing to be seen in-person by their treating physician for a Baseline visit (with first dose of the advanced therapy occurring within 14 days), and at 16 (+/- 5 days) and 24 weeks (+14 days) calculated based on date of first dose of the advanced therapy and must provide informed consent prior to enrolling in the study or completing study-specific questionnaires or procedures. Data will be collected from both subjects and their treating dermatology provider at predetermined scheduled intervals (Baseline, Week 16 and Week 24) using a structured and standardized data collection tool.

Conditions

Psoriasis

Outcome Measures

Primary Outcomes (1)

• Creation of a cohort of psoriasis subjects

  Creation of a cohort of psoriasis subjects to describe the changes at 16 and 24 weeks after initiation of advanced therapy. The changes will be determined by completion of questionnaires

  Baseline (Day 0), Week 16 and 24 weeks after initiation of advanced therapy

Interventions

Observational (Non-Interventional) Registry OTHER

This is an observational (non-interventional) registry

Also known as: This is an observational (non-interventional) registry

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Study population must be at least 18 years of age and is initiating advanced therapy for the treatment of moderate-to-severe plaque PSO. Eligible patients must be willing to be seen in-person by their treating physician for a Baseline visit (with first dose of the advanced therapy occurring within 14 days), and at 16 (+/- 5 days) and 24 weeks (+14 days) calculated based on date of first dose of the advanced therapy and must provide informed consent prior to enrolling in the study or completing study-specific questionnaires or procedures.

You may qualify if:

• To be eligible to participate in this study, an individual must meet all the following criteria:
• Patient is at least 18 years of age at the time of study enrollment.
• Patient has a diagnosis of moderate to severe plaque psoriasis based on an investigator Global Assessment (IGA, score of 3 or 4 at the time of Enrollment).
• Patient is initiating new Eligible Medication for the first time for the treatment of PSO.
• Patient is willing and able to provide informed consent to participate in this study.

You may not qualify if:

• An individual who meets any of the following criteria will be excluded from participation in the study:
• Patient is participating in a blinded clinical trial.
• Patients that do not receive at least 1 dose of the advanced therapy within 14 days following the Enrollment/Baseline visit for the study.
• Patients cannot be concurrently enrolled in both the CorEvitas PSO Registry and the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study. A. Patients currently enrolled in the CorEvitas PSO Registry are ineligible for participation in the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study.
• B. Patients otherwise meeting eligibility criteria can be enrolled in the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study C. Following completion or at time of Exit from the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study, patients will be eligible to enroll into the CorEvitas PSO Registry for long term follow-up at the standard of care cadence supported by the registry. A separate Informed consent will be obtained.

Sponsors & Collaborators

• CorEvitas: lead

Study Sites (2)

CorEvitas, LLC

Waltham, Massachusetts, 02451, United States

RECRUITING

CorEvitas, LLC

Waltham, Massachusetts, 02451, United States

NOT YET RECRUITING

MeSH Terms

Conditions

Psoriasis

Interventions

Registries

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Records; Organization and Administration; Health Services Administration; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Central Study Contacts

Cathy Cheney

CONTACT

+1 508 408 5433; corevitasregistrytrials@corevitas.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 26 Weeks
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 5, 2026
• First Posted: June 15, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): December 31, 2036
• Study Completion (Estimated): December 31, 2036
• Last Updated: June 15, 2026

Record last verified: 2026-06

Locations

US (2)